The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials
<h3>Background</h3><p dir="ltr"><u>Metabolic syndrome</u> (MetS) is a chronic disorder featuring overweight/obesity, high blood pressure, and dysfunction of lipid and <u>carbohydrate metabolism</u>. Microbiome-modulating<u> probiotics, prebio...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513540543479808 |
|---|---|
| author | Ridhima Kaul (12485902) |
| author2 | Pradipta Paul (12628162) Manale Harfouche (4557211) Muhammad Ayyan (16328986) Sa'ad Laws (19772763) Ali Chaari (827168) |
| author2_role | author author author author author |
| author_facet | Ridhima Kaul (12485902) Pradipta Paul (12628162) Manale Harfouche (4557211) Muhammad Ayyan (16328986) Sa'ad Laws (19772763) Ali Chaari (827168) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ridhima Kaul (12485902) Pradipta Paul (12628162) Manale Harfouche (4557211) Muhammad Ayyan (16328986) Sa'ad Laws (19772763) Ali Chaari (827168) |
| dc.date.none.fl_str_mv | 2024-08-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.dsx.2024.103118 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/The_effect_of_microbiome-modulating_therapeutics_on_glucose_homeostasis_in_metabolic_syndrome_A_systematic_review_meta-analysis_and_meta-regression_of_clinical_trials/30024046 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Medical biochemistry and metabolomics Nutrition and dietetics Pharmacology and pharmaceutical sciences Microbiome Personalized precision medicine Diabetes Hypertension Obesity |
| dc.title.none.fl_str_mv | The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr"><u>Metabolic syndrome</u> (MetS) is a chronic disorder featuring overweight/obesity, high blood pressure, and dysfunction of lipid and <u>carbohydrate metabolism</u>. Microbiome-modulating<u> probiotics, prebiotics, synbiotics</u> and <u>fecal microbiota</u> transplant (FMT) are promising adjunct therapies for improving parameters of <u>glucose homeostasis</u> and insulinemia. </p><h3>Methods</h3><p dir="ltr">We conducted a comprehensive <u>systematic review</u>, meta-analyses, and meta-regressions to investigate the effect of the abovementioned microbiome therapies on various biomarkers after screening <u>clinical trials</u> published through April 2023. We pooled data using random effects meta-analyses, reporting them as mean differences (MDs) with 95 % confidence intervals (CIs), and conducting univariate linear model meta-regressions. </p><h3>Results</h3><p dir="ltr">Data from 21 trial comparisons across 19 studies (n = 911) revealed that, compared to placebo/control, microbiome-modulating therapies were associated with statistically significant changes in fasting <u>plasma glucose</u> (MD: 4.03 mg/dL [95%CI: 6.93; −1.13]; p<sub>effect</sub> = 0.006, I<sup>2</sup> = 89.8 %), and fasting insulin (MD: 2.56 μU/mL [95%CI: 4.28; −0.84]; p<sub>effect</sub> = 0.004, I<sup>2</sup> = 87.9 %), but not insulin resistance or sensitivity indices and <u>HbA1c</u>. Age, baseline <u>BMI</u>, baseline biomarker value, pro/synbiotic dosage, trial duration, <u>nutraceutical</u> type, and WHO region were factors affecting the efficacy of these interventions at producing changes in biomarkers, signaling the potential role of personalized precision medicine adjunct therapy for deranged <u>glucose homeostasis</u> in patients with MetS. Nevertheless, presence of heterogeneity calls for further investigation before their clinical application. </p><h3>Conclusions</h3><p dir="ltr">Probiotics, <u>prebiotics, synbiotics </u>and FMT supplementation improved fasting glucose and insulin in patients with MetS. Further large-scale and high-quality trials are required before potential clinical applications.</p><h2>Other Information</h2><p dir="ltr">Published in: Diabetes & Metabolic Syndrome: Clinical Research & Reviews<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.dsx.2024.103118" target="_blank">https://dx.doi.org/10.1016/j.dsx.2024.103118</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_343c66ab7f4176b3fc8eab538d339564 |
| identifier_str_mv | 10.1016/j.dsx.2024.103118 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30024046 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trialsRidhima Kaul (12485902)Pradipta Paul (12628162)Manale Harfouche (4557211)Muhammad Ayyan (16328986)Sa'ad Laws (19772763)Ali Chaari (827168)Biomedical and clinical sciencesClinical sciencesMedical biochemistry and metabolomicsNutrition and dieteticsPharmacology and pharmaceutical sciencesMicrobiomePersonalized precision medicineDiabetesHypertensionObesity<h3>Background</h3><p dir="ltr"><u>Metabolic syndrome</u> (MetS) is a chronic disorder featuring overweight/obesity, high blood pressure, and dysfunction of lipid and <u>carbohydrate metabolism</u>. Microbiome-modulating<u> probiotics, prebiotics, synbiotics</u> and <u>fecal microbiota</u> transplant (FMT) are promising adjunct therapies for improving parameters of <u>glucose homeostasis</u> and insulinemia. </p><h3>Methods</h3><p dir="ltr">We conducted a comprehensive <u>systematic review</u>, meta-analyses, and meta-regressions to investigate the effect of the abovementioned microbiome therapies on various biomarkers after screening <u>clinical trials</u> published through April 2023. We pooled data using random effects meta-analyses, reporting them as mean differences (MDs) with 95 % confidence intervals (CIs), and conducting univariate linear model meta-regressions. </p><h3>Results</h3><p dir="ltr">Data from 21 trial comparisons across 19 studies (n = 911) revealed that, compared to placebo/control, microbiome-modulating therapies were associated with statistically significant changes in fasting <u>plasma glucose</u> (MD: 4.03 mg/dL [95%CI: 6.93; −1.13]; p<sub>effect</sub> = 0.006, I<sup>2</sup> = 89.8 %), and fasting insulin (MD: 2.56 μU/mL [95%CI: 4.28; −0.84]; p<sub>effect</sub> = 0.004, I<sup>2</sup> = 87.9 %), but not insulin resistance or sensitivity indices and <u>HbA1c</u>. Age, baseline <u>BMI</u>, baseline biomarker value, pro/synbiotic dosage, trial duration, <u>nutraceutical</u> type, and WHO region were factors affecting the efficacy of these interventions at producing changes in biomarkers, signaling the potential role of personalized precision medicine adjunct therapy for deranged <u>glucose homeostasis</u> in patients with MetS. Nevertheless, presence of heterogeneity calls for further investigation before their clinical application. </p><h3>Conclusions</h3><p dir="ltr">Probiotics, <u>prebiotics, synbiotics </u>and FMT supplementation improved fasting glucose and insulin in patients with MetS. Further large-scale and high-quality trials are required before potential clinical applications.</p><h2>Other Information</h2><p dir="ltr">Published in: Diabetes & Metabolic Syndrome: Clinical Research & Reviews<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.dsx.2024.103118" target="_blank">https://dx.doi.org/10.1016/j.dsx.2024.103118</a></p>2024-08-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.dsx.2024.103118https://figshare.com/articles/journal_contribution/The_effect_of_microbiome-modulating_therapeutics_on_glucose_homeostasis_in_metabolic_syndrome_A_systematic_review_meta-analysis_and_meta-regression_of_clinical_trials/30024046CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/300240462024-08-01T00:00:00Z |
| spellingShingle | The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials Ridhima Kaul (12485902) Biomedical and clinical sciences Clinical sciences Medical biochemistry and metabolomics Nutrition and dietetics Pharmacology and pharmaceutical sciences Microbiome Personalized precision medicine Diabetes Hypertension Obesity |
| status_str | publishedVersion |
| title | The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials |
| title_full | The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials |
| title_fullStr | The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials |
| title_full_unstemmed | The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials |
| title_short | The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials |
| title_sort | The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials |
| topic | Biomedical and clinical sciences Clinical sciences Medical biochemistry and metabolomics Nutrition and dietetics Pharmacology and pharmaceutical sciences Microbiome Personalized precision medicine Diabetes Hypertension Obesity |